Efe, C. Et Al. 2012. Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome. AUTOIMMUNITY REVIEWS , vol.11, no.5 , 330-334.

Efe, C., Ozaslan, E., KAV, T., Purnak, T., Shorbagi, A., ÖZKAYAR, Ö., ... Berlot, A. H.(2012). Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome. AUTOIMMUNITY REVIEWS , vol.11, no.5, 330-334.

Efe, Cumali Et Al. "Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome," AUTOIMMUNITY REVIEWS , vol.11, no.5, 330-334, 2012

Efe, Cumali Et Al. "Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome." AUTOIMMUNITY REVIEWS , vol.11, no.5, pp.330-334, 2012

Efe, C. Et Al. (2012) . "Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome." AUTOIMMUNITY REVIEWS , vol.11, no.5, pp.330-334.

@article{article, author={Cumali Efe Et Al. }, title={Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome}, journal={AUTOIMMUNITY REVIEWS}, year=2012, pages={330-334} }